TC (Docetaxel and Cyclophosphamide) adjuvant chemotherapy:

Aspect	Details
Chemotherapy Regimen	Docetaxel and Cyclophosphamide (TC)
Cycles	4 cycles
Schedule	Every 2 weeks (dose-dense) or every 3 weeks (standard)
Dosing	Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m²
Toxicity	Common: Neuropathy, Rash, Palmar-Plantar Erythrodysesthesia Grade 3 effects in some patients (9.8% for rash and palmar/plantar erythrodysesthesia) Low rate of neutropenic fever (2.5%)
Outcomes	Disease-free survival: 81% at 7 years Overall survival: 87% at 7 years
Benefits	– Effective for node-negative and low-risk node-positive breast cancer – Less cardiotoxicity compared to anthracycline-based regimens – Rapid completion (8-10 weeks) with minimal toxicity – Similar or superior efficacy to doxorubicin and cyclophosphamide (AC) regimen
Risks	– Risk of neutropenia – Potential for significant rash – Long-term effects not fully understood – May be less effective than sequential anthracycline-taxane regimens for some high-risk patients

 

Citations:

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000576/

[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475113/

[3] https://jamanetwork.com/journals/jamaoncology/fullarticle/2443153

[4] https://emedicine.medscape.com/article/1946040-overview